The Paradigm Shift in Biopharmaceutical Infrastructure

The biopharmaceutical industry has entered an era defined by the need for unprecedented agility. The demand for personalized medicines, the rapid development timelines spurred by global health crises, and the economic pressure to reduce the cost of goods sold (COGS) are forcing a fundamental re-evaluation of manufacturing infrastructure. At the center of this transformation is the widespread adoption and evolution of single-use systems (SUS). No longer merely a convenient alternative to stainless steel, SUS are rapidly becoming the foundational technology for flexible, scalable, and rapidly deployable biomanufacturing capacity.

This shift represents more than a simple change in equipment material. It is a comprehensive rethinking of facility design, quality control, supply chain management, and regulatory strategy. For stakeholders in bioprocessing, from process development scientists to facility engineers and C-suite executives, understanding the trajectory of single-use technology is not optional—it is strategic. This article provides an in-depth analysis of the forces shaping the future of SUS, the innovations driving them forward, and the challenges that must be addressed to fully realize their potential.

The Evolution of Single-Use Technologies in Modern Bioprocessing

A Legacy of Rigidity and the Promise of Flexibility

For decades, stainless steel was the undisputed standard for biopharmaceutical manufacturing. While robust and durable, these fixed-in-place systems demanded massive capital investment, extensive infrastructure for cleaning-in-place (CIP) and sterilization-in-place (SIP), and prolonged validation timelines. A facility built for one product was often prohibitively expensive to reconfigure for another, creating a significant barrier to flexibility. The rise of multi-product facilities and contract development and manufacturing organizations (CDMOs) exposed the inherent rigidity of the stainless steel paradigm.

Single-use systems emerged as a direct response to these limitations. By utilizing pre-sterilized, disposable components—bioreactors, mixers, tubing assemblies, filters, and connectors—SUS eliminated the need for cross-product cleaning validation. This led to dramatically reduced changeover times, lower water and energy consumption, and a sharp reduction in the risk of cross-contamination. The initial adoption in early-stage clinical manufacturing quickly validated the technology, proving that high-quality biologics could be produced in these new platforms.

Current State of Adoption Across Modalities

Today, single-use technology is deeply embedded across the entire bioprocessing workflow. In upstream processing, single-use bioreactors (SUBs) ranging from 50L to 2000L are standard workhorses for fed-batch and perfusion cultures. In downstream processing, single-use membrane chromatography, virus filtration, and tangential flow filtration (TFF) systems have become routine. Even fill-finish operations are increasingly adopting closed, single-use isolator systems to maintain sterility and flexibility.

The adoption is not uniform but is heavily concentrated in specific modalities. For the production of monoclonal antibodies (mAbs), SUS are dominant in clinical and small-to-medium commercial batches. For novel modalities like cell and gene therapies (CGT), viral vectors, and mRNA-based therapeutics, single-use systems are not just preferred—they are often the only viable option due to the need for absolute sterility, closed processing, and the small-scale, patient-specific nature of the products. This widespread acceptance has laid the groundwork for the next wave of innovation.

Defining the Next Generation: Innovation Pathways for SUS

Material Science and Film Technology Frontiers

The performance of any single-use system is intrinsically tied to the quality of the polymer film used to construct bioreactors and storage bags. Early films suffered from issues related to leachables and extractables (E/L), which could negatively impact sensitive cell lines or interfere with analytical assays. The future of SUS hinges on advanced materials that address these limitations head-on.

Manufacturers are now deploying multi-layer films with exceptional gas barrier properties, often incorporating ethylene-vinyl alcohol (EVOH) copolymers. These advanced films drastically reduce oxygen ingress and CO2 egress, providing a more stable environment for cell culture. Furthermore, new film formulations are being engineered to be more robust, reducing the risk of failure during handling, and more resistant to shear stress in stirred-tank reactors. Advanced material platforms like the Flexsafe range from Sartorius demonstrate how targeted film engineering can improve consistency, reduce E/L profiles, and support high-density cell cultures. The race is on to develop films that combine mechanical strength, chemical compatibility, and biological inertness while also addressing end-of-life sustainability.

The Symbiosis of Automation and Digitalization

A major criticism of early SUS was the relative lack of sophisticated process control compared to traditional stainless-steel reactors equipped with advanced sensors. This gap is rapidly closing thanks to the integration of smart technologies. The emergence of cost-effective, single-use sensors (SU sensors) for critical process parameters (CPPs) such as pH, dissolved oxygen (DO), temperature, and glucose/lactate is transforming disposable bioreactors from simple containers into intelligent control units.

These sensors are typically pre-calibrated and pre-sterilized, eliminating the calibration drift and contamination risks associated with reusable probes. When combined with Process Analytical Technology (PAT) frameworks, these sensors enable real-time monitoring and control, facilitating advanced feeding strategies and automated harvest decisions. The integration of smart single-use technologies is paving the way for digital twins, where a virtual replica of the bioprocess is continuously updated with real-time data from SUS sensors. This allows for predictive modeling, anomaly detection, and process optimization without interrupting the physical production run. The "smart" single-use system is a cornerstone of the fully digitalized biomanufacturing facility of the future.

Modular and Scalable Facility Architectures

The physical design of biomanufacturing facilities is being reshaped by single-use technology. The traditional stick-built, classically classified cleanroom is giving way to modular, ballroom-style layouts. In a ballroom configuration, multiple single-use bioreactors and processing trains are placed in a large, unclassified or controlled space, relying on the closed nature of the SUS for containment rather than the room itself.

This approach offers incredible capital efficiency. A facility built around SUS can be constructed in a fraction of the time (12-18 months vs. 3-5 years for stainless steel) and at a significantly lower cost. This modularity also enables scalability through parallelism—rather than building one massive reactor, manufacturers can simply add more standardized single-use trains. This "scale-out" strategy is particularly valuable for products with uncertain demand, such as new gene therapies or pandemic vaccines, allowing capacity to be deployed in lockstep with clinical success.

Addressing the Critical Hurdles: Sustainability, Supply Chains, and Standardization

The Environmental Imperative

The most significant and widely discussed challenge facing single-use technology is its environmental footprint. The plastic waste generated by a busy biomanufacturing facility is substantial, consisting of bags, tubing, filters, and cartridges that are typically incinerated for biohazard safety, or in some cases, sent to landfill. This creates a tension between the immediate benefits of SUS (speed, safety, sterility) and the long-term corporate goal of environmental sustainability.

The industry is actively confronting this challenge through several complementary strategies. First, suppliers are reducing the volume of plastic used in their products without compromising strength. Second, robust recycling programs are being developed. Companies like Triumvirate Environmental offer specialized services for collecting and recycling non-hazardous plastic waste from bioprocessing. Leading suppliers like Cytiva are investing heavily in comprehensive sustainability initiatives that focus on product design, operational efficiency, and circular economy principles. While a fully biodegradable, single-use bioprocess bag is still on the horizon, the focus on mass balance approaches—where virgin plastic consumption is offset by recycling credits or chemically recycled feedstock—is a pragmatic step forward.

Fortifying Supply Chain Resilience

The COVID-19 pandemic exposed the fragility of global supply chains, and the biopharma industry was not immune. The reliance on specialized polymers and components from a limited number of suppliers created significant vulnerabilities. A single disruption, whether from a factory shutdown, shipping crisis, or raw material shortage, could halt critical production lines.

Future-proofing SUS requires a multi-pronged approach to supply chain management. Dual sourcing and multi-sourcing of critical components is becoming standard practice. Manufacturers are increasingly qualifying alternative suppliers for bags, filters, and tubing to ensure redundancy. The trend towards regional manufacturing hubs, where key components are produced closer to the point of use, is also gaining momentum. Furthermore, stronger partnerships and data-sharing agreements between suppliers and end-users are fostering greater transparency, allowing for earlier warning signs of potential disruptions. The goal is a resilient, agile supply network that can absorb shocks without impacting the availability of life-saving medicines.

The Drive for Standardization and Interoperability

Vendor lock-in has long been a concern for manufacturers adopting SUS. The inability to easily swap a bag from one supplier with a bag from another due to differences in port configurations, film dimensions, or connector types limits flexibility and can create dependencies. Industry bodies such as the BioPhorum Operations Group (BPOG) and the Bio-Process Systems Alliance (BPSA) are leading the charge to establish universal standards.

Standardization efforts focus on physical interfaces (e.g., port sizes, spacing, and connector types) and functional performance (e.g., hold times, mixing characteristics, and filter capacity). Wider adoption of standardized designs will allow manufacturers to mix and match components from different suppliers with greater confidence, fostering competition and reducing costs. For CDMOs operating multi-client facilities, interoperability is not just a convenience—it is an operational necessity. The future of SUS is one where a bioreactor bag is as interchangeable as a laboratory pipette tip, allowing for seamless integration within a global supply ecosystem.

Strategic Outlook for the Biomanufacturing Leader

Hybrid Models and Total Cost of Ownership

The future is not a binary choice between single-use and stainless steel. The most advanced manufacturers are moving towards hybrid facilities that strategically deploy both technologies. A typical model might use single-use trains for clinical manufacturing, early commercial launch, or low-volume/high-value products (like gene therapies), while reserving large-scale, dedicated stainless steel lines for high-volume, mature blockbusters (like major mAbs).

The decision framework for this hybrid model is increasingly driven by a sophisticated Total Cost of Ownership (TCO) analysis. This analysis goes beyond simple equipment cost to include factors like water-for-injection (WFI) consumption, labor for cleaning and assembly, energy costs for sterilization, facility footprint, and changeover time. For many modern facilities, the economic breakeven point for SUS versus stainless steel has moved upwards, making single-use the more cost-effective option for a wider range of batch sizes than ever before.

Enabling the Modalities of Tomorrow

Looking forward, the role of SUS will be most critical in enabling the production of advanced therapy medicinal products (ATMPs). Cell and gene therapies require highly closed, sterile, and flexible processing systems to ensure patient safety and product consistency. The decentralized manufacturing model being explored for some cell therapies will rely entirely on compact, automated, single-use platforms. Similarly, the rapid production of mRNA vaccines and viral vectors for in vivo gene editing is dependent on the speed and flexibility that only single-use systems can provide. BioProcess International consistently highlights single-use as the core enabling technology for these cutting-edge modalities.

Conclusion: Embracing an Agile, Sustainable, and Intelligent Manufacturing Paradigm

The future of single-use systems in biopharmaceutical manufacturing is one of maturation and integration. The technology has already moved beyond the "disruptor" phase to become an established, indispensable tool in the bioprocessing toolkit. The next decade will see SUS evolve through advancements in material science, digitalization, and standardization.

The ultimate success of this technology will be defined by the industry's ability to solve its greatest challenge: sustainability. By addressing the environmental impact head-on through innovation in materials and recycling, and by fortifying supply chains against future disruptions, the biopharmaceutical industry can fully unlock the potential of single-use systems. The result will be a manufacturing landscape that is more responsive to patient needs, more resilient to global shocks, and more efficient in delivering the next generation of life-changing therapies to the world. The shift is not just about disposables; it is about building a fundamentally smarter and more adaptable approach to biomanufacturing.